Two gene-therapy trial deaths in China raise oversight concerns

September 8, 2026 at 05:00 AM1 min

This digest was compiled by AI from multiple sources — links to the originals are below.

Two children died in separate gene-therapy trials in China, raising questions about oversight and potential impact on the country's biomedical industry. The trials involved ethics breaches and lacked transparency, with one death revealed only after an investigation by Science and Retraction Watch. Researchers expect stronger regulations for gene-therapy trials as a result.

Key Facts

Two children died in separate gene-therapy trials in China, according to researchers, ethicists and legal scholars.
Both trials were fast-tracked as investigator-initiated trials (IITs), which allow researchers to test therapies without supervision from China's drug regulator.
One death was revealed only after an investigation by Science and Retraction Watch.
Researchers expect the deaths to prompt stronger regulations for gene-therapy trials in China.

Trial Oversight Failures

The two trials involved breaches of ethics and lacked transparency, according to researchers, ethicists and legal scholars. Both trials were fast-tracked as investigator-initiated trials (IITs), enabling researchers in China to test therapies quickly without supervision from the country's drug regulator. IITs are widely considered a driving force behind China's rising competitiveness in biomedicine. One death was only revealed after an investigation by Science and Retraction Watch.

Regulatory Response Expected

Researchers say the deaths will probably prompt the introduction of stronger regulations for gene-therapy trials. Legal scholar Hank Greely cautioned that a balance must be struck, stating, "We can't make ethics so tight that no research can ever possibly be done." The deaths could have a profound effect on China's biomedical industry, according to researchers.